Genomic PRKCQ amplification contributed to the constitutive activation of TCR signaling in malignant T cells.
CTCL
DELETION
Previous studies from our group and others reported PD-1 expression on malignant T cells in 19%–39.4% of CTCL cases (To explore the mechanism underlying the tumor-suppressive activity of PD-1 signaling in this patient and assess the presence of oncogenic TCR activation, we performed both whole-exome sequencing (WES) and whole-genome sequencing (WGS) on the patient’s PBMCs before anti–PD-1 treatment. Data from WES identified 52 nonsynonymous SNVs, 4 nonsense SNVs, and 1 frame shift deletion (To explore whether 